Victory Capital Management Inc. Makes New $216,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)

Victory Capital Management Inc. bought a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,716 shares of the company’s stock, valued at approximately $216,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. purchased a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $1,118,000. Bank of New York Mellon Corp grew its stake in shares of Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after buying an additional 18,755 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $532,000. American Century Companies Inc. grew its stake in shares of Keros Therapeutics by 24.9% in the 2nd quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock worth $13,626,000 after buying an additional 59,364 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Bank of America cut their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Wedbush restated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Guggenheim began coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Trading Down 1.4 %

Shares of KROS opened at $57.74 on Friday. The business’s fifty day simple moving average is $59.49 and its two-hundred day simple moving average is $52.29. Keros Therapeutics, Inc. has a 12 month low of $27.31 and a 12 month high of $73.00. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -11.08 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million for the quarter. During the same quarter last year, the firm earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -5.28 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.